BRIEF-Zynerba Pharmaceuticals announces initiation of FAB-c exploratory Phase 2 clinical trial
January 03, 2017 at 07:35 AM EST
* Zynerba Pharmaceuticals announces initiation of the fab-c exploratory phase 2 clinical trial of zyn002 cbd gel in patients with fragile x syndrome
